Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
For cash-pay customers, pricing begins at $149 per month with manufacturer-sponsored savings offers applied automatically before checkout
The proven cardiovascular benefits of semaglutide, particularly the reduction in major adverse cardiovascular events demonstrated in the SELECT trial, also influence the decision for those with heart disease risk factors
Lilly Cares Patient Assistance program Lilly Cares provides free Zepbound to income-qualifying uninsured patients
US$ 23.89
US$ 20.21
US$ 27.48
US$ 25.31
